ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Seroprevalence of West Nile virus, Greece, 2020.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Seroprevalence of West Nile virus among blood donors in mainland France, 2021 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Decoding tRNA dynamics in neuroimmune disorders: mechanistic insights, diagnostic innovations, and therapeutic opportunities.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundWest Nile virus (WNV) is a growing public health concern in Europe. Greece is one of the most affected countries in Europe, with the highest annual incidences.AimWe aimed at assessing IgG antibodies to WNV in the Greek population and compared the results with a nationwide survey conducted in the period 2012-2013.MethodsIn a geographically stratified sampling, 4,416 serum samples were collected and analysed for WNV-specific IgG antibodies using ELISA. Samples positive for WNV IgG were further tested with a WNV serum neutralisation test to detect false positives.ResultsThe weighted seroprevalence, adjusted for age, sex and region, was 2.83% (95% confidence interval (CI): 2.32-3.44) in the 4,416 samples tested, significantly higher than in the 2012-2013 survey (1.55%; 95% CI: 1.17-2.04). The seropositivity increased with age with the highest seroprevalence in persons aged ≥ 80 years (6.04%; 95% CI: 3.28-10.88). No significant differences in seropositivity were observed between sexes or regions. We estimated that 312 (95% CI: 256-379) persons had a WNV infection per a case of West Nile neuroinvasive disease (WNND). A certain degree of discordance was observed between areas with increased seroprevalence and those with an increased incidence of WNND.ConclusionOur study reveals a wider geographical spread of WNV infections in Greece compared with previous investigations. The nearly twofold increase in seroprevalence highlights the need for ongoing monitoring and preventive measures to mitigate the impact of WNV on public health in Greece.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.